eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 15
Systematic review/Meta-analysis

Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis

Man Jin, Yali Mo, Kaisheng Ye, Mingxian Chen, Yi Liu, Cao He

Arch Med Sci 2019; 15, 1: 23–32
Online publish date: 2017/07/31
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Functional dyspepsia (FD) is typically treated with serotonin receptor (5-HT) agonists such as cisapride, mosapride, tegaserod and tandospirone citrate. However, there are conflicting efficacy data, possibly due to significant heterogeneity between studies. In this meta-analysis, we analyzed the efficacy and safety data from studies evaluating the efficacy of serotonin receptor agonists in patients with FD.

Material and methods
Relevant studies were selected from the Medline, Cochrane, EMBASE, and Google Scholar databases. The meta-analysis included 10 RCTs which evaluated the efficacy of serotonin receptor agonists in patients with FD (final total of 892 patients in the serotonin receptor agonist group, and 640 participants in the placebo group). The primary outcomes were the response rates and abdominal symptoms score. The Cochrane Collaboration’s tool was used to assess risk. Sensitivity analysis was carried out using the leave-one-out approach.

Patients treated with serotonin receptor agonists had a significantly higher response rate compared to placebo-treated patients (pooled OR = 2.99; 95% CI: 1.15–7.77; p = 0.025). Patients treated with serotonin receptor agonists had a significant improvement in symptom scores compared to the placebo group (pooled standardized mean difference = –0.43; 95% CI: –0.83 to –0.04; p = 0.031). Sensitivity analysis indicated that the pooled estimates for abdominal symptom score might be affected by the Yeoh et al. (1997) study.

Serotonin receptor agonists had a significantly higher efficacy compared to placebo in the treatment of FD.


functional dyspepsia, serotonin receptor, efficacy, placebo, meta-analysis

Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 Suppl 2: II37-42.
Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol Suppl 1991; 182: 47-60.
Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015; 64: 1049-57.
Yarandi SS, Christie J. Functional dyspepsia in review: pathophysiology and challenges in the diagnosis and management due to coexisting gastroesophageal reflux disease and irritable bowel syndrome. Gastroenterol Res Pract 2013; 2013: 351086.
Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl 1996; 215: 38-47.
Gisbert JP, Calvet X, Gabriel R, Pajares JM. [Helicobacter pylori infection and functional dyspepsia. Meta-analysis of efficacy of eradication therapy]. Med Clin (Barc) 2002; 118: 405-9.
Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000; 321: 659-64.
Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N. Helicobacter pylori eradication therapy for functional dyspepsia: systematic review and meta-analysis. World J Gastroenterol 2016; 22: 3486-95.
Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007; 22: 304-10.
Lu Y, Chen M, Huang Z, Tang C. Antidepressants in the treatment of functional dyspepsia: a systematic review and meta-analysis. PLoS One 2016; 11: e0157798.
Talley NJ. Functional dyspepsia: new insights into pathogenesis and therapy. Korean J Intern Med 2016; 31: 444-56.
Talley NJ; American Gastroenterological A. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129: 1753-5.
Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; 4: CD001960.
Huang X, Lv B, Zhang S, Fan YH, Meng LN. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012; 18: 7371-7.
Degen L, Petrig C, Studer D, Schroller S, Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005; 17: 821-6.
Mawe GM, Hoffman JM. Serotonin signalling in the gutfunctions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013; 10: 473-86.
Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 959-67.
Amano T, Ariga H, Kurematsu A, et al. Effect of 5-hydroxytryptamine receptor 4 agonist mosapride on human gastric accommodation. Neurogastroenterol Motil 2015; 27: 1303-9.
de Groot GH, de Both PS. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. Aliment Pharmacol Ther 1997; 11: 193-9.
Yeoh KG, Kang JY, Tay HH, et al. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. J Gastroenterol Hepatol 1997; 12: 13-8.
Kellow JE, Cowan H, Shuter B, et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9: 153-60.
Van Outryve M, De Nutte N, Van Eeghem P, Gooris JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol Suppl 1993; 195: 47-52; discussion-3.
al-Quorain A, Larbi EB, al-Shedoki F. A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol 1995; 30: 531-4.
Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009; 104: 2779-87.
Tack J, Van Den Elzen B, Tytgat G, et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2009; 21: 619-26, e23-4.
Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007; 22: 1566-70.
Allescher HD, Bockenhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-41.
Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689-96.
Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989; 11: 169-77.
Collaboration TC. Cochrane Handbook for Systematic. Reviews of Interventions. Version 5.1.0 Updated March 2011.
Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
Vakil N, Kianifard F, Bottoli I. Exploratory study of tegaserod for dyspepsia in women receiving PPIs for heartburn. Arch Drug Inf 2008; 1: 79-88.
Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414.
Camilleri M. Functional dyspepsia and gastroparesis. Dig Dis 2016; 34: 491-9.
Hongo M, Harasawa S, Mine T, et al. Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol 2012; 27: 62-8.
Tack J, Janssen P, Bisschops R, Vos R, Phillips T, Tougas G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. Neurogastroenterol Motil 2011; 23: e32-9.
Bang CS, Kim JH, Baik GH, et al. Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol 2015; 30: 28-42.
Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 1291-9.
Wang B, Liang X, Jia B. [A controlled multi-centre clinical trial on cisapride in treatment of functional dyspepsia]. Zhonghua Nei Ke Za Zhi 1995; 34: 180-4.
Rosch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987; 22: 161-4.
Jian R, Ducrot F, Ruskone A, et al. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657-64.
Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987; 28: 300-5.
Karamanolis GP, Tack J. Current management of functional dyspepsia: impact of Rome III subdivision. Ann Gastroenterol 2012; 25: 96-9.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe